Latigo Biotherapeutics, Inc.
Foresite Capital funds converted 9,041,328 derivative securities into Latigo Biotherapeutics (LTGO) common shares and bought 140,000 more at $18.00 per share on August 10, 2026, following LTGO's IPO. The funds now indirectly hold 3,414,544 LTGO shares, disclaiming beneficial ownership beyond pecuniary interest.
Latigo Biotherapeutics (LTGO) priced its IPO at $18, opened at $21, and raised $350M. LTG-001 showed 50% greater pain relief than hydrocodone in a 343-patient trial. Phase 3 trials are planned for 2026-2027. The company has $69.4M in cash and reported net losses of $109.2M in 2025.
James B. Tananbaum, via funds managed by Foresite Capital, disclosed a 14.5% stake in Latigo Biotherapeutics, Inc. in a Schedule 13D filed Aug. 17, 2026, after the company’s Aug. 10, 2026 IPO. The filing says there are no current plans for major transactions or board changes, though shares may be bought or sold.
Over the past 7 days, alphai's AI scored 1 news story mentioning LTGO (Latigo Biotherapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LTGO coverage spans financial news, ipo and insider activity.
In the last 30 days, LTGO insiders filed 2 SEC Form 4 transactions — 2 purchases ($5.0M) and no sales. The most active reporter was Foresite Capital Management V, LLC with 1 filing.
Significant dilution from conversion and a modest insider purchase increase ownership stakes.
The IPO creates immediate liquidity and a sizable cash runway, likely supporting upcoming Phase 3 trials and driving short‑term price volatility.
James B. Tananbaum, via funds managed by Foresite Capital, disclosed a 14.5% stake in Latigo Biotherapeutics, Inc. in a Schedule 13D filed Aug. 17, 2026, after the company’s Aug. 10, 2026 IPO. The filing says there are no current plans for major transactions or board changes, though shares may be bought or sold.
Foresite Capital funds and management, led by James B. Tananbaum, filed a Schedule 13D for Latigo Biotherapeutics (ALMS) common stock, reporting ownership changes after prior purchases of Series A-2 and Series B convertible preferred at set prices and a $3.5M convertible note. A 1-for-6.42441 reverse split occurred July 28, 2026, and preferred converted with Latigo’s Aug. 10 IPO.
IPO pricing and early trading momentum are supported by disclosed clinical efficacy and a reset of funding runway via gross proceeds.
alphai scores every news story that mentions LTGO with an AI model for sentiment and relevance, and aggregates insider trades from Latigo Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Foresite Capital funds converted 9,041,328 derivative securities into Latigo Biotherapeutics (LTGO) common shares and bought 140,000 more at $18.00 per share on August 10, 2026, following LTGO's IPO. The funds now indirectly hold 3,414,544 LTGO shares, disclaiming beneficial ownership beyond pecuniary interest.
2 min readLatigo Biotherapeutics (LTGO) priced its IPO at $18, opened at $21, and raised $350M. LTG-001 showed 50% greater pain relief than hydrocodone in a 343-patient trial. Phase 3 trials are planned for 2026-2027. The company has $69.4M in cash and reported net losses of $109.2M in 2025.
2 min readJames B. Tananbaum, via funds managed by Foresite Capital, disclosed a 14.5% stake in Latigo Biotherapeutics, Inc. in a Schedule 13D filed Aug. 17, 2026, after the company’s Aug. 10, 2026 IPO. The filing says there are no current plans for major transactions or board changes, though shares may be bought or sold.
2 min readForesite Capital funds and management, led by James B. Tananbaum, filed a Schedule 13D for Latigo Biotherapeutics (ALMS) common stock, reporting ownership changes after prior purchases of Series A-2 and Series B convertible preferred at set prices and a $3.5M convertible note. A 1-for-6.42441 reverse split occurred July 28, 2026, and preferred converted with Latigo’s Aug. 10 IPO.
6 min readLatigo Biotherapeutics (NASDAQ:LTGO) priced its IPO at $18 and opened at $21, raising nearly $350 million. Shares later traded around $19.38. The clinical-stage company targets non-opioid pain via selective Nav1.8 inhibitors, including LTG-001, which met a Phase 2 abdominoplasty endpoint. Cash was $69.4M at Dec. 31, 2025, with going-concern language in its S-1.
7 min readForesite Capital Management V, LLC purchased 140,000 indirectly-held shares of Latigo Biotherapeutics, Inc. (LTGO) at $18.00 ($2.52M total) on 2026-08-10.
2 min readTananbaum James B. purchased 140,000 indirectly-held shares of Latigo Biotherapeutics, Inc. (LTGO) at $18.00 ($2.52M total) on 2026-08-10.
2 min readLatigo Biotherapeutics, a Thousand Oaks biotech developing non-opioid pain medicines, IPOed Aug. 6. According to the company, it raised $345.6 million in an upsized offering, selling 19.2 million shares at $18 (vs. 16 million at $16-$18). Shares began trading on Nasdaq Aug. 7 as LTGO and closed at $18.25.
2 min readThe page is a roundup of personal finance, ETF, and stock-pick pieces plus IPO and market-mover items. It notes Latigo Biotherapeutics priced an IPO at $18 raising $345.6M, BlossomHill priced at $16 raising $150M, and Ticketplus priced at $8 raising $15M. It also lists big gainers like Airbnb and losers like Trade Desk.
6 min readLatigo Biotherapeutics IPO raised $346M to fund its non-opioid pain pipeline, including LTG-001, a NaV1.8 blocker targeting Phase 3. In a Phase 2b abdominoplasty trial (343 patients), both doses reduced pain vs placebo; only the high dose cut opioid rescue use. Latigo says meaningful relief began in 52 minutes. Shares began trading on Nasdaq as LTGO.
6 min read
